This section shows a summary for the selected study (COSU identifier) or publication (COSP identifier). Studies may have been performed by the Sanger Institute Cancer Genome Project, or imported from the ICGC/TCGA. You can see more information on the help pages.
- A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
- Paper ID
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Research Initiative for ALK-Related Malignancies, Cambridge, United Kingdom. Electronic address: firstname.lastname@example.org.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019;14(11):e257-e259
PMID: 31668326 (view at PubMed or Europe PMC)
- Paper Status